Voluntis (Euronext Paris, Ticker: VTX – ISIN: FR0004183960) announces today the appointment of Guillaume Floch as Chief Financial Officer, following the departure of Matthieu Plessis.
Guillaume Floch, 44 years old, has more than 20 years of professional experience in finance, first in an audit firm, then in the biopharmaceutical sector in financial control and then in financial management. In particular, he held the position of Chief Financial Officer of Hybrigenics (biotechnology) for more than 10 years, after having been Administrative and Financial Manager at Zeneus Pharma (acquired by Cephalon). Guillaume holds a DESCF and a MSTCF from the University of Paris V.
Pierre Leurent, CEO of Voluntis, said:
“I would like to thank Matthieu Plessis for his very effective contribution to our activities over the last few years. We are delighted to welcome Guillaume Floch to our team and Guillaume will bring his strong experience in the life sciences sector to support the new stage of the company’s development, in line with our strategic roadmap”.
Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self- manage their treatment every day, thus improving real-world outcomes. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to the patient and the care team so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. These real-time recommendations are based on digitized clinical algorithms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in diabetes and oncology. Voluntis has long-standing partnerships with leading life science companies. Based out of Boston and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.